Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs

American Journal of Medicine

Volumn 105, Issue 1 B, 1998, Pages 20S-30S

  Cryer, Byron ^a   Kimmey, Michael B ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

CONFERENCE PAPER; DUODENUM ULCER; DYSPEPSIA; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; HUMAN; INTESTINE STENOSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; STOMACH ULCER;

EID: 0032572546     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00071-0     Document Type: Conference Paper

References (140)

1. Semble EL, Wallace CWJ, Castell DO. Non-steroidal anti-inflammatory drugs and esophageal injury. Semin Arthritis Rheum. 1989;19:99-109.
2. Wolfsen HC, Wang KK. Etiology and course of acute bleeding esophageal ulcers. J Clin Gastroenterol. 1992;14: 342-346.
3. Heller SR, Fellows IW, Ogilvie AL, Atkinson M. Non-steroidal anti-inflammatory drugs and benign esophageal stricture. BMJ. 1982;285:167-168.
4. Wilkins WE, Ridley MG, Pozniak AL. Benign stricture of the oesophagus: role of non-steroidal anti-inflammatory drugs. Gut. 1984;25:478-480.
5. Davenport HW. Damage to the gastric mucosa: effects of salicylates and stimulation. Gastroenterology. 1965;49: 189-196.
6. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol. 1983;245:601-623.
7. Cryer B, Feldman M. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal anti-inflammatory drug-induced damage. Arch Intern Med. 1992;152:1145-1155.
8. 2. Gastroenterology. 1987;93:744-752.
9. Cryer B, Goldschmiedt M, Redfern JS, Feldman M. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. Gastroenterology. 1990;99:1616-1621.
10. Laine L, Sloane R, Ferretti M, Cominelli F. A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc. 1995;42:428-433.
11. Lanza FL, Karlin DA, Yee JP. A double-blind placebo-controlled endoscopic study comparing the mucosal injury seen with an orally and parenterally administered new nonsteroidal analgesic ketorolac tromethamine at therapeutic and supratherapeutic doses. (Abstr.) Am J Gastroenterol. 1987;82:939.
12. Lanza FL, Umbenhauer ER, Nelson RS, et al. A double-blind randomized placebo-controlled gastroscopic study to compare the effects of indomethacin capsules and indomethacin suppositories on the gastric mucosa of human volunteers. J Rheumatol. 1982;9:415-419.
13. Collins AJ, Davies J, Dixon AS. A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis. Br J Rheumatol. 1988;27:106-109.
14. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348:1413-1416.
15. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol. 1990;259:462-467.
16. Wallace JL, Hogaboam CM, Kubes P. Immunopathology of NSAID-gastropathy: inhibitory effects of interleukin-I and cyclosporin A. Ann N Y Acad Sci. 1992;664:400-407.
17. Vaananen PM, Keenan CM, Grisham MB, Wallace JL. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation. 1992;16:227-240.
18. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. (Review.) Gastroenterology. 1997;112:1000-1016.
19. Wallace JL, Reuter B, Cicala C, et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 1994; 107:173-179.
20. Graham DY, Lidsky MD, Cox AM, et al. Long-term non-steroidal antiinflammatory drug use and Helicobacter infection. Gastroenterology. 1991;100:1653-1657.
21. Kim JG, Graham DY. Helicobacter pylori infection and development of gastric or duodenal in arthritic patients receiving chronic NSAID therapy. The Misoprostol Study Group. Am J Gastroenterol. 1994;89:203-207.
22. Bianchi-Porro G, Parente F, Imbesi V, et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long-term NSAID users. Response to omeprazole dual therapy. Gut. 1996;39:22-26.
23. Chan FKL, Sung JJY, Chung SCS, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975-979.
24. Lanas A, Chandra Sekar M, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology. 1992;103:862-869.
25. Silvoso GR, Ivey KJ, Butt JH, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 1979;91:517-520.
26. Lockard OO Jr, Evey KJ, Butt JH, et al. The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspirin therapy. Gastrointest Endosc. 1980;26: 5-7.
27. Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992;327:749-754.
28. Somerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet. 1986;1:462-464.
29. Wilcox CM, Shalek KA, Cotsonis G. Striking prevalence of over-the-counter non-steroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med. 1994;154:42-46.
30. Perua DA, Lanza FL, Gostout CJ, et al. The American College of Gastroenterology Bleeding Registry: preliminary findings. Am J Gastroenterol. 1997;92:924-928.
31. Larkai EN, Smith JL, Lidsky MD, et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol. 1989; 11:158-162.
32. Talley NJ, Evans JM, Fleming KC, et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci. 1995;40:1345-1350.
33. Fries JF, Williams CA, Block DA. The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1991;34:1353-1360.
34. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 1987;82:1153-1158.
35. Roth SH. Efficacy of antacid therapy for NSAID-induced symptomatic gastropathy. (Abstr.) Am J Gastroenterol. 1993;88:1516.
36. Bijlsma JW. Treatment of endoscopy-negative NSAID-induced upper gastrointestinal symptoms with cimetidine: an international multicentre collaborative study. Aliment Pharmacol Ther. 1988;2(suppl 1):75-83.
37. Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic Multicentre Study. Scand J Gastroenterol. 1996;31:753-758.
38. Caldwell JR, Roth SH, Wu WC, et al. Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage. Am J Med. 1987;83(suppl 3B):74-82.
39. Collins AJ, Davies J, Dixon AStJ. Contrasting presentation and findings between patients with rheumatic complaints taking nonsteroidal anti-inflammatory drugs and a general population referred for endoscopy. Br J Rheumatol. 1986; 25:50-53.
40. Kimmey MD, Silverstein FE, Saunders DR, Chapman RC. Reduction of endoscopically assessed acute aspirin-induced gastric mucosal injury with cimetidine. Dig Dis Sci. 1987;32:851-856.
41. Graham DY, Smith JL, Dobbs SM. Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci. 1983;28:1-6.
42. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988;2:1277-1280.
43. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med. 1993;119:257-262.
44. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 1993;153:2565-2571.
45. Cameron AJ. Aspirin and gastric ulcer. Mayo Clin Proc. 1975;50:565-570.
46. Graham DY, Smith JL. Aspirin and the stomach. (Review.) Ann Intern Med. 1986;104:390-398.
47. Lanza FL Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol. 1993;88:1318-1323.
48. Langman MJS. Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. (Review.) Gastroenterology. 1989;96(2 suppl):640-646.
49. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991; 114:257-263.
50. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ. 1990;300:278-284.
51. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787-796.
52. Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology. 1997;112:683-689.
53. Carson JL, Strom BL, Soper KA, et al. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med. 1987;147:85-88.
54. Fries JF, Williams CA, Block DA, Michael BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91:213-222.
55. Silverstien FE, Graham Dy, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249.
56. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735-740.
57. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153: 1665-1670.
58. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology. 1993;105:1078-1088.
59. Garcia-Rodriguez LA, Jick HA. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343: 769-772.
60. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:1075-1078.
61. Henry D, Lim LL-Y, Garcia-Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312:1563-1566.
62. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulcers. Gut. 1991; 32:252-255.
63. Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in non-steroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 1997;112:1817-1822.
64. Walan A, Bader JP, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med. 1989;320: 69-75.
65. Hawkey CJ, Florén I, Langstrom G, et al. Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users - the Omnium study. (Abstr.) Gastroenterology. 1997;112:A144.
66. Roth S, Bennett R, Caldron P, et al. Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): an endoscopic study. Semin Arthritis Rheum. 1990;194(suppl 2):11-19.
67. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344-350.
68. Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for NSAID users. (Abstr.) Gastroenterology. 1996;110:A86.
69. Hawkey CJ, Swannell AJ, Eriksson S, et al. Lower frequency of gastroduodenal ulcers and erosions and dyspeptic symptoms in NSAID users during maintenance with omeprazole compared to ranitidine. (Abstr.) Gastroenterology. 1996;110:A130.
70. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial ranitidine. BMJ. 1988;297:1017-1021.
71. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci. 1989;34: 424-428.
72. Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1993;153:2449-2454.
73. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med. 1996; 334:1435-1439.
74. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med. 1991;115:195-200.
75. Cryer B, Gottesdiener K, Gertz B, et al. Effects of a novel cyclooxygenase (COX-2) inhibitor on gastric mucosal prostaglandin (PG) synthesis in healthy humans. (Abstr.) Am J Gastroenterol. 1996;91:1907.
76. Lanza FL, Rack MF, Callison DA, et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2-selective inhibitor. (Abstr.) Gastroenterology. 1997; 112:A194.
77. Lichtenberger LM, Wang ZM, Romero JJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) associated with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med. 1995;1:154-158.
78. Langman MJS, Morgan L, Worral A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrahage. BMJ. 1985;290:347-349.
79. Day TK. Intestinal perforation associated with osmotic slow release indomethacin capsules. BMJ. 1983;287: 1671-1672.
80. Madhok R, MacKenzie JA, Lee FD, et al. Small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs for rheumatoid arthritis. Q J Med. 1986;58: 53-58.
81. Deakin M. Small bowel perforation associated with an excessive dose of slow release diclofenac sodium. BMJ. 1988;297:488-489.
82. Saw KC, Quick CRG, Higgins AF. Ileocecal perforation and bleeding - are non-steroidal anti-inflammatory drugs (NSAIDs) responsible? J R Soc Med. 1990;83:114-115.
83. Sturges HF, Krone CL Ulceration and stricture of the jejunum in a patient on long-term indomethacin therapy. Am J Gastroenterol. 1973;59:162-169.
84. Nagaraj HS, Sandhu AS, Cook LN, et al. Gastrointestinal perforation following indomethacin therapy in very low birth weight infants. J Pediatr Surg. 1981;16:1003-1007.
85. Morris AJ, Madhok R, Sturrock RD, et al. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet. 1991;337: 520.
86. Bjarnason I, Hayllar J, Macpherson AJ, Russel AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104:1832-1847.
87. Matsuhashi N, Yamada A, Hiraishi M, et al. Multiple strictures of the small intestine after long-term nonsteroidal anti-inflammatory drug therapy. Am J Gastroenterol. 1992; 87:1183-1186.
88. Saverymuttu SH, Thomas A, Grundy A, Maxwell JD. Ileal stricturing after long-term indomethacin treatment. Postgrad Med J. 1986;62:967-968.
89. Levi S, Delacy G, Price AB, et al. "Diaphragm-like" strictures of the small bowel in patients treated with nonsteroidal anti-inflammatory drugs. Br J Radiol. 1990;63: 186-189.
90. Bjarnason I, Zanelli G, Smethurst P, et al. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. Gastroenterology. 1988; 94:1070-1074.
91. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988;109:359-363.
92. Sukumar L. Recurrent small bowel obstruction with piroxicam. (Abstr.) Br J Surg. 1987;74:186.
93. Johnson F. Recurrent small bowel obstruction with piroxicam. (Abstr.) Br J Surg. 1987;74:654.
94. Lang J, Price AB, Levi AJ, et al. Diaphragm disease: the pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drug. J Clin Path. 1988; 41:516-526.
95. Bjarnason I, Prouse P, Smith T, et al. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet. 1987;2:711-714.
96. Bjarnason I, Zanelli G, Smith T, et al. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology. 1987;93:480-489.
97. Morris AJ, Wasson LA, MacKenzie JF. Small bowel enteroscopy in undiagnosed gastrointestinal blood loss. Gut. 1992;33:887-889.
98. Kendall MJ, Hawkins CF. Xylose test: effects of aspirin and indomethacin. BMJ. 1971;1:533-536.
99. Dyer NH, Kendall MJ, Hawkins CG. Malabsorption in rheumatoid arthritis. Ann Rheum Dis. 1971;30:626-630.
100. Petterson T, Wegelius O, Skrifvars B. Gastro-intestinal disturbances in patients with severe rheumatoid arthritis. Acta Med Scand. 1970;1-2:139-144.
101. Bjarnason I, Williams P, So A, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of nonsteroidal anti-inflammatory drugs. Lancet. 1984;2:1171-1174.
102. Kepczyk T, Kadakia SC. Prospective evaluation of gastrointestinal tract in patients with iron-deficiency anemia. Dig Dis Sci. 1995;40:1283-1289.
103. Cook IJ, Pavli P, Riley JW, et al. Gastrointestinal investigation of iron deficiency anaemia. BMJ. 1986;292:1380-1382.
104. 51Cr method and chemical tests in patients referred for colonoscopy. Scan J Gastroenterol. 1984;19:245-254.
105. Vreugdenhil G, Wognum AW, van Eijk HG, Swaak AJG. Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness. Ann Rheum Dis. 1990;49:93-98.
106. Bjarnason I, Williams P, Smethurst P, et al. Effect of nonsteroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut. 1986; 27:1292-1297.
107. Morris AJ, Howden CW, Robertson C, et al. Increased intestinal permeability in ankylosing spondylitis - primary lesion or drug effect? Gut. 1991;32:1470-1472.
108. Mielants H, DeVos M, Goemaere S, et al. Intestinal mucosal permeability in inflammatory rheumatic diseases II. Role of disease. J Rheumatol. 1991;18:394-400.
109. Bjarnason I, Fehilly B, Smethurst P, et al. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut. 1991;32:275-277.
110. Mielants H, Goemaere S, DeVos M, et al. Intestinal mucosal permeability in inflammatory rheumatic diseases I. Role of antiinflammatory drugs. J Rheumatol. 1991;18: 389-393.
111. Anthony A, Dhillon AP, Nygard G, et al. Early histological features of small intestinal injury induced by indomethacin. Aliment Pharmacol Ther. 1993;7:29-39.
112. Morris AJ, Murray L, Sturrock RD, et al. Short report: the effect of misoprostol on the anaemia of NSAID enteropathy. Aliment Pharmacol Ther. 1994;8:343-346.
113. Davies GR, Wilkie ME, Rampton DS. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci. 1993;38: 417-425.
114. Stamm CP, Pearce WA, Larsen BA, et al. Colonic ulcerations associated with non-steroidal anti-inflammatory ingestion. (Abstr.) Gastrointest Endosc. 1991;37:260.
115. Debenham GP. Ulcer of the cecum during oxyphenbutazone (tanderil) therapy. Can Med Assoc J. 1966;94:1182-1184.
116. Charuzi I, Ovnar A, Zirkin H, et al. Ibuprofen and benign cecal ulcer. J Rheumatol. 1985;12:188-189.
117. Uribe A, Johansson C, Scezak P, Rubio C. Ulceration of the colon associated with naproxen and acetylsalicylic acid treatment. Gastrointest Endosc. 1986;32:242-244.
118. Bravo AC, Lowman RM. Benign ulcer of sigmoid colon. An unusual lesion that can stimulate carcinoma. Radiology. 1968;90:113-115.
119. Carson J, Notis WM, Orris ES. Colonic ulceration and bleeding during diclofenac therapy. (Letter.) N Engl J Med. 1990;323:135.
120. Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature. Arch Intern Med. 1992; 152:625-632.
121. Ravi S, Keat AC, Keat ECB. Colitis caused by non-steroidal anti-inflammatory drugs. Postgrad Med J. 1986;62: 773-776.
122. Huber T, Ruchti C, Halter F. Nonsteroidal antiinflammatory drug-induced colonic strictures: a case report. Gastroenterology. 1991;100:1119-1122.
123. Bridges AJ, Marshall JB, Diaz-Arias AA. Acute eosinophilic colitis and hypersensitivity reaction associated with naproxen therapy. Am J Med. 1990;89:526-527.
124. Giardiello FM, Hansen III FC, Lazenby AJ, et al. Collagenous colitis in the setting of nonsteroidal anti-inflammatory drugs and antibiotics. Dig Dis Sci. 1990;35:257-260.
125. Woolf DL Indomethacin suppositories. (Abstr.) BMJ. 1965;1:1497.
126. Berry H, Seinson D, Jones H, Hamilton EBD. Indomethacin and naproxen suppositories in the treatment of rheumatoid arthritis. Ann Rheum Dis. 1978;37:370-372.
127. Bunney RG. Non-steroidal anti-inflammatory drugs and the bowel. Lancet. 1989;2:1047-1048.
128. Doman DB, Goldberg HJ. A case of meclofenamate sodium-induced colitis. Am J Gastroenterol. 1986;81:1220-1221.
129. Tanner AR, Raghunat H. Colonic inflammation and nonsteroidal anti-inflammatory drug administration. An assessment of the frequency of the problem. Digestion. 1988;41:116-120.
130. Hansen TM, Matzen P, Madsen P. Endoscopic evaluation of the effect of indomethacin capsules and suppositories on the gastric mucosa in rheumatic patients. J Rheumatol. 1984;11:484-487.
131. Wright V, Hopkins R. A note on indomethacin suppositories in rheumatic conditions. Rheumatol Rehabil. 1979;18: 186-187.
132. Walls J, Bell D, Schora W. Rectal bleeding and indomethacin. (Abstr.) BMJ. 1968;1:52.
133. Levy N, Gaspar E. Rectal bleeding and indomethacin suppositories. (Letter.) Lancet. 1975;305:577.
134. Gizzi G, Villani V, Brandi G, et al. Anorectal lesions in patients taking suppositories containing non-steroidal anti-inflammatory drugs (NSAID). Endoscopy. 1990;22: 146-148.
135. Coutrot S, Roland D, Barbier J, et al. Acute perforation of colonic diverticula associated with short term indomethacin. Lancet. 1978;2:1055-1056.
136. Gossum AV, Zalcu M, Adler M, et al. Anorectal stenosis in patients with prolonged use of suppositories containing paracetamol and acetylsalicylic acid. Dig Dis Sci. 1993; 38:1970-1977.
137. 4 and prostanoid release: relating to ethanol-induced injury. Br J Pharmacol. 1988;93:937-943.
138. Campbell K, Steele RJC. Non-steroidal anti-inflammatory drugs and complicated diverticular disease: a case-control study. Br J Surg. 1991;78:190-191.
139. Wilson RG, Smith AN, Macintyre IMC. Complications of diverticular disease and non-steroidal anti-inflammatory drugs: a prospective study. Br J Surg. 1990;77:1103-1104.
140. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med. 1987;107:513-516.